Genetic Markers and Clinical Relevance in Rheumatoid Arthritis
Jianping Guo,Zhanguo Li
DOI: https://doi.org/10.1111/1756-185x.12812
2015-01-01
International Journal of Rheumatic Diseases
Abstract:Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease that primarily affects peripheral joints. The etiology of RA remains unknown, but it is widely accepted that genetic factors play a major role in RA pathogenesis. The genetic contribution in RA is supported by evidence from twin studies. That is, monozygotic twins display excess disease concordance (12–20%), when compared with dizygotic twins (4–5%). Further evidence is that the relative risk of RA in siblings compared with that in the general population (recurrence-risk ratio in siblings, λs) has been described to be between 2 and 17. It has been estimated that the genetic contribution to RA susceptibility is approximately 60%. The genetic factors are believed to influence not only disease susceptibility but also severity. Furthermore, a number of risk genes have been shown to be specifically associated with anti-citrullinated protein antibodies (ACPA)-positive or -negative RA. Additionally, RA is more prevalent in women, with a female-to-male ratio of ~3 : 1. Although sex hormones have been considered to be candidates responsible for the gender bias, sex-specific genetic factors also play a role in RA susceptibility. ACPAs are of particular interest, since these autoantibodies are highly specific for RA with a specificity of 98%, and can be approximately found in 70% of RA patients. It makes ACPA an important clinical biomarker for RA diagnosis. Evidence from studies of ACPA-positive and -negative disease subsets suggests that they are two different diseases in distinct genetic susceptibility. Meanwhile, a number of studies also suggested that some of the susceptibility loci were shared between ACPA-positive and -negative RA. HLA: The association of human leukocyte antigen (HLA) genes with RA susceptibility was first described in 1976. It still remains the best described genetic risk factor contributing to RA, of which, the HLA-DR molecules seem to be most powerful recognized genetic risk factors, contributing at least 30% of the total genetic effects, especially the HLA-DRβ1.1 Increase in the frequencies of DRβ1*0101, *0102, *0401, *0404, *0405, *0408, *1001 and *1402 were reported in RA patients in different ethnic groups. These HLA-DRβ1 alleles encode a conserved amino acid sequence (QKRAA, QRRAA or RRRAA) at position 70–74 of the DR beta 1 chain. This conserved sequence is referred to as the shared epitope (SE). In addition to DRβ1, the HLA-DQ molecules may also play a role in RA susceptibility. However, the contribution of DQ genes to RA is undistinguishable from DRβ1, due to the strong linkage disequilibrium. Accumulating data have shown that the HLA-DRβ1 SE particularly confers risk to ACPA-positive RA but not to ACPA-negative RA in Caucasians.2-4 The SE-dependent DR-DQ haplotype SE-DQ3/4/5 remained in strong association with both ACPA -positive and -negative RA in a Han population.5 A recent study identified a novel association at amino acid position 77 in HLA-A with ACPA-positive RA.6 The interaction between the presence of double copies of DRβ1-SE alleles and smoking increased a great risk for development of RA.7 Furthermore, a strong interaction of DRβ1-SE, the protein tyrosine phosphatase non-receptor 22 (PTPN22) and smoking was identified for development of RA in the presence of specific ACPA reactivities, that is, the presence of antibodies to citrullinated α-enolase and vimentin.8 Non-HLA genes: One of the putative non-HLA genes that is associated with RA is PTPN22. The PTPN22 association concerns the minor allele of the non-synonymous single nucleotide polymorphism (SNP) rs2476601 (C1858T, R620W). PTPN22 is associated almost exclusively with the ACPA-positive RA.7, 9 Interestingly, the T allele is almost absent in African American and Asian populations.1 Other non-HLA genes have also been suggested to confer ACPA-positive RA. For example, a locus between tumor necrosis factor (TNF) receptor-associated factor 1 (TRAF1) and complement component 5 (C5) has been identified as a genetic risk factor for RA, particularly being associated with ACPA-positive RA, in a genome-wide scan association study.10 Peptidylarginine deiminase citrullinating enzyme 4 (PADI4) is one of several peptidylarginine deiminase enzymes that catalyze the conversion of arginine residues into citrulline, and this may be related to the production of anti-citrulline antibodies. The association between PADI4 and RA, particularly with ACPA-positive RA, was originally reported in a Japanese case–control study11 and has been replicated in several Asian populations.12, 13 However, the RA association studies of PADI4 in European populations have produced conflicting results.9, 14 An association of sprouty-related EVH1 domain-containing protein 2 (SPRED2) locus was reported in an expanded meta-analysis of six genome-wide association studies in anticyclic citrullinated peptide antibody (anti-CCP)-positive RA patients in Caucasians.15 In a genome-wide association study of a Han population,16 the top SNPs at the three non-major histocompatibility complex (non-MHC) loci were associated with both ACPA-positive and -negative RA, but the association signals were all stronger in ACPA-positive patients than in ACPA-negative patients. In the same study, the C-C chemokine receptor type 6 variants showed strong association in ACPA-positive RA patients but not in ACPA-negative RA patients, which is consistent with previous studies in White Europeans.15 A genetic study in twins has estimated the heritability of anti-CCP antibody-negative RA is approximately 66%, similar to the heritability of anti-CCP positive RA, estimated at 68%. In the same study, the SE alleles were found to explain 18% of the genetic component of RA susceptibility in anti-CCP-positive RA but only 2.4% in anti-CCP-negative RA.17 Another study investigated HLA-DRβ1 susceptibility and protective models for RA association after stratification according to anti-CCP status in Caucasians. Significant associations between several HLA-DRβ1 alleles and anti-CCP negative RA were found.18 The work by Viatte et al.19 showed a strong association of the SE with anti-CCP-negative RA in UK Caucasian patients. Two recent studies of ACPA-negative patients identified a strong association at two amino acid positions, that is, HLA-DRβ1 position 11 and HLA-β position 9.6, 20 These two positions have also been shown to be associated with ACPA-positive RA. Interestingly, the presence of a serine residue at HLA-DRβ1 position 11 conferred risk of ACPA-negative disease but was protective against ACPA-positive disease.6 Several non-HLA genes have also been shown to be associated with anti-CCP-negative RA. Candidate gene association studies and a subsequent meta-analysis have confirmed an association of signal transducer and activator of transcription 4 (STAT4) polymorphisms with anti-CCP-positive and -negative RA.21 Interferon regulatory factor 5 polymorphisms have been shown to be more strongly associated with anti-CCP-negative RA than with anti-CCP-positive RA in Caucasians.22 Dendritic cell immunoreceptor (DCIR) polymorphisms rs2377422 have been shown to have a significant association with ACPA-negative RA in Swedish and Asian populations.23, 24 The variants at ANKRD55/IL6ST, BLK and PTPN22 showed association with anti-CCP negative RA.19 In contrast to the enormous progress in genetics of RA susceptibility during the past years, the number of studies in genetics of RA severity is relatively limited. Based on the study in an Icelandic population, the heritability of radiologic progression in RA patients was estimated at 45–58%.25 The RA patients who carried the HLA-DRβ1 SE alleles had higher levels of radiological damage.26 The presence of DERAA-encoding HLA-DRβ1 alleles conferred a lower risk of radiographic destruction in RA patients.27 The genes outside of the MHC region have also been suggested to be associated with RA severity. Knevel et al. investigated GZMB as a candidate gene accounting for the severity of joint destruction in RA, and found the SNP rs8192916 located in GZMB was associated with the progression of joint destruction.28 RA patients carrying risk alleles of Dkk-1 had higher serum levels of functional Dkk-1 and more progressive joint destruction over time.29 The functional LILRA3 appears to confer a higher risk to disease severity in early RA patients.30 Two SNPs, rs451066 on chromosome 14 and rs11908352 on chromosome 20, near the gene matrix metallopeptidase 9 (MMP-9) were associated with the severity of joint destruction in RA. Rs11908352 may influence joint destruction via MMP-9 production.31 However, the majority of the genetic studies in RA severity were underpowered and with moderate effect, and needs to be replicated in independent cohorts. To date, there have been a limited number of studies investigating the sex-specific genetic factors in RA susceptibility. Vandenbroeck et al.32 reported that several polymorphisms in the IFNγ/IL-26 gene region may contribute to female bias in susceptibility to RA. The frequency of the PTPN22 1858T allele was increased excessively in male RA patients, compared to female patients in a German cohort.33 A study of 2963 patients with RA and 1731 controls in UK Caucasians revealed that the FCGR3A-158F/V variant was a risk factor for the development of autoantibody-positive RA, particularly in men.34 More recently, the functional LILRA3 was found as a novel genetic risk factor for RA susceptibility, especially in males.30 One of the ultimate goals of genetic studies is to predict the disease prior to onset, disease severity and drug response. Indeed, there have been several studies concerning genetic factors in predicting disease risk. In Yarwood's work, a weighted genetic risk score (wGRS) was created using 45 RA non-HLA susceptibility loci, imputed amino acids at HLA-DRβ1 (11, 71 and 74), HLA-DPβ1 (position 9) HLA-β (position 9) and gender. The wGRS was tested in 11 366 RA cases and 15 489 healthy controls. It is found that individuals in the highest risk group showed significantly increased odds of developing ACPA-positive RA compared to the lowest risk group.35 Another study combined odds ratios for 25 HLA-DRβ1 alleles, 31 RA-susceptible SNPs and ever-smoking status in males to determine RA risk. They showed that HLA and smoking provided strongest prediction with good discrimination. SNPs provided minimal prediction. High risks from the HLA model were associated with younger onset RA. Ever-smoking associated with older onset disease.36 Although there is evidence of genetic contribution to RA severity, the majority of the studies had a relatively low statistical power and have not been replicated. Thus, current risk genes might not be able to predict disease severity sufficiently for clinical practice. Regarding the genetic markers in prediction of response to treatment, there are a number of publications reporting the association between known RA-susceptible genes and several approved RA therapeutics. Several studies have shown the SNP G308A in the gene encoding TNF-α was associated with clinical responses to infliximab, etanercept and adalimumab, and most studies reported an increased efficacy.37 Significant association was found between the FCGR2A H131R polymorphism and the response to treatment with infliximab, but not with the other two TNF inhibitors, etanercept and adalimumab.38 In addition, IL-6R polymorphisms rs12083537, rs2228145 and rs4329505 have been shown to be potential predictors for response to tocilizumab in RA.39 By a three-stage trans-ethnic meta-analysis, Okada et al.40 not only discovered 42 novel RA risk loci at a genome-wide level of significance, but also demonstrated that these genes are the targets of approved therapies for RA, including tocilizumab (anti-IL6R), tofacitinib (Janus-activated kinase 3 inhibitor), and abatacept (cytotoxic T-lymphocyte-associated protein 4 immunoglobulin). However, some studies have reported very inconsistent results in predicting therapeutic responses. Moreover, despite a number of genes having been shown as possibly predicting therapeutic responses, the role of these genes in the pathogenesis of RA remains elusive. Therefore, further functional studies will hopefully elucidate the roles of these genetic markers involved in RA pathogenesis and therapeutic responses. In summary, genetic factors play important roles in RA susceptibility. Some susceptibility genes appear to specifically predispose to ACPA-positive or ACPA-negative RA. There is evidence of genetic contribution to RA severity; however, the majority of the studies had low statistical power and yielded to inconclusive results. In addition, several genetic factors displayed sex bias in RA susceptibility. Furthermore, a number of RA genetic susceptibility variants were also implicated in the prediction of individuals who are at risk of disease, or therapeutic responses to RA therapies. It indicates that the utility of genetic studies lie not only in being able to identify the genetic risks involved in RA susceptibility, but also in the possible prognostic markers for early diagnosis of RA, and the molecules or biological pathways that could be potentially target and lead to better treatment of RA. This study was supported in part by the National Natural Science Foundation of China (No: 81120108020, No. 31270914, and No. 31470875). The authors declare that there is no conflict of interests regarding the publication of this paper.